DMOG (Dimethyloxaloylglycine) is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolyl hydroxylase.
|Source||Int J Biol Sci (2018). Figure 3. DMOG|
|Incubation Time||48 h|
|Results||The number of surviving BMSCs cultured in normoxic condition was 8.3×10^3. The number of surviving cells number was 3.9×10^4 in the DMOG-treated group.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Related HIF Products|
Desidustat is an inhibitor of HIF hydroxylase.
LW6 is a novel HIF-1alpha inhibitor, with an IC50 of 4.4 μM.
Enarodustat (JTZ-951) is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM.
PT2385 is an orally active, selective inhibitor of hypoxia inducible factor (HIF)-2alpha, with a Ki value of less than 50 nM.
JNJ-42041935 is a potent, competitive, reversible, and selective inhibitor of PHD with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.